Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


A new vaccine therapy for brain cancer


MEDIA RELEASE

29 November 2012

A new vaccine therapy for brain cancer

What do you do when you are faced with terminally ill patients that want to trial a promising immunotherapy but are too sick to provide the immune cells necessary for it to work? If you are Wellington-based Neurosurgeon Mr Martin Hunn, you head back to the laboratory and find another way.

Glioblastoma multiforme (GBM) is a highly aggressive brain tumour, with an extremely poor prognosis.

The standard treatments for GBM are surgery, radiotherapy and chemotherapy, but the tumour rapidly becomes resistant to these therapies, making it ultimately fatal in almost all cases. There is an urgent need to develop novel therapies for this disease.

“We hypothesised that by acting through entirely different mechanisms, therapies that activate the immune system might succeed in attacking GBM tumours where standard treatments have failed,” says Mr Hunn.

Immunotherapy has been explored as a potential treatment option for brain cancers for some time. Here in New Zealand, Mr Hunn, along with colleagues at Wellington Hospital and the Malaghan Institute, recently completed a Phase I GBM vaccine trial at Wellington Hospital, the outcomes of which will be available next year.

The vaccines used in these trials are typically created from the patient’s tumour tissue – the target, and dendritic cells - the immune cells that direct the anti-tumour immune response.

“The problem however is that some GBM patients are so unwell it can be difficult to isolate enough dendritic cells from their blood to prepare a vaccine,” says Mr Hunn.

In parallel to his clinical work, Mr Hunn therefore undertook some laboratory-based research in collaboration with Associate Professor Ian Hermans and colleagues from the Malaghan Institute, to see if they could simplify their approach by removing the need for dendritic cells to be present in the vaccine.

Their research, published recently in the peer-reviewed international journal Clinical Cancer Research, shows that a vaccine consisting of only tumour cells and an immune-boosting adjuvant is an effective treatment for brain tumours (gliomas) in a mouse model.

“Our research has shown that we can evoke a tumour-specific, long-lasting immune response that is strong enough to kill glioma tumours by targeting the activation of dendritic cells already present inside the mouse,” says Mr Hunn. “In some instances we saw the complete disappearance of tumour lesions as detected by magnetic resonance imaging.”

One of the reasons Mr Hunn thinks this new immunotherapy approach has such great promise is because of the adjuvant included in the vaccine to boost the anti-tumour immune response – a compound derived from marine sponges called alpha-galactosylceramide (alpha-GalCer).

While this new vaccine therapy has been developed in mice, early indications are that GBM cancer patients have the immune system ‘machinery’ required for the therapy to work equally well in humans.

”We believe our research has identified a simple vaccine that could be an effective treatment for a group of patients who currently face an extremely poor prognosis,” says Mr Hunn.

This research was supported by the Cancer Society of New Zealand, the Neurological Foundation of New Zealand, the Wellington Medical Research Foundation and Just Paterson Real Estate. Mr Hunn was supported by a New Zealand Health Research Council Clinical Fellowship, the Royal Australasian College of Surgeons and the Surgical Research Trust.

Research Publication Details
Hunn MK, Farrand KJ, Broadley KW, Weinkove R, Ferguson P, Miller RJ, Field CS, Petersen T, McConnell MJ, Hermans IF Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma. Clin Cancer Res, 2012 Nov 12 [Epub ahead of print]

About the Malaghan Institute of Medical Research
The Malaghan Institute of Medical Research is New Zealand’s leading vaccine and immunology research institute and is based at Victoria University of Wellington’s Kelburn campus. The Institute operates independently and is a charitable trust. Researchers at the Malaghan Institute are focused on developing innovative ways to harness the strength and potency of the immune system, the body’s own natural defence against disease, to treat cancer, asthma and allergy, arthritis, multiple sclerosis and infectious disease.


Mr Martin Hunn

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Floods: Initial Assessment Of Economic Impact

Authorities around the region have compiled an initial impact assessment for the Ministry of Civil Defence, putting the estimated cost of flood recovery at around $120 million... this early estimate includes social, built, and economic costs to business, but doesn’t include costs to the rural sector. More>>

ALSO:

Food: Govt Obesity Plan - No Tax Or Legislation

Speaking to Q+A’s Corin Dann this morning, health minister Jonathan Coleman said tackling obesity was at the top of the Government’s priority list, but there was “no evidence” a sugar tax worked, and further regulation was unnecessary. More>>

ALSO:

Treasury Docs On LVR Policy: Government Inaction Leads To Blurring Of Roles

The Treasury wouldn’t have had to warn the Reserve Bank to stick to its core functions if the Government had taken prompt and substantial measures to rein in skyrocketing Auckland house prices, Labour’s Finance spokesperson Grant Robertson says. More>>

ALSO:

Final EPA Decision: Tough Bar Set For Ruataniwha Dam

Today’s final decision by the Tukituki Catchment Board of Inquiry is good news for the river and the environment, says Labour’s Water spokesperson Meka Whaitiri. “Setting a strict level of dissolved nitrogen in the catchment’s waters will ensure that the dam has far less of an impact on the Tukituki river." More>>

ALSO:

"Don’t Give Up":
End Of Kick-Start Hits KiwiSaver Enrolments

ANZ said new enrolments for the ANZ KiwiSaver Scheme had dropped by more than 50% since the Government announced an immediate end to the $1,000 KiwiSaver kick-start incentive in the Budget last month. More>>

ALSO:

Serious Fraud Office: Alex Swney Receives Jail Sentence

Former Chief Executive of Heart of the City Alex Swney has been sentenced to five years and seven months’ imprisonment for charges brought respectively by the Serious Fraud Office (SFO) and the Inland Revenue. More>>

ALSO:

Get More From Scoop

 
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news